Medtech & Life SciencesOncology · Diagnostics · Biotech
Designation
Sesh
Precision immuno-oncology, mapping the immune response to cancer.
Fig. 10 - Liquid biopsy biomarker detection arraySan Diego, CA
Classification
SectorMedtech & Life Sciences
SystemLiquid biopsy diagnostics
FounderAndrew Sinkoe, Ph.D.
OriginSan Diego, CA
PositionPre-Seed
The Mission
Early-stage cancer detection still relies on invasive biopsies and imprecise imaging. Sesh is developing a precision immuno-oncology liquid biopsy — a blood test that maps cancer-specific biomarkers to detect disease earlier, monitor treatment response, and guide therapeutic decisions with a simple blood draw.
Signal - Public Milestones
◆Developing liquid biopsy blood test for cancer biomarker detection and immune response profiling
◆Won $200K grand prize at the 2026 SDSU San Diego Angel Conference
◆Supported by Connect, EvoNexus, National Cancer Institute, and Brink SBDC